Estithmar Holding Reports an Exceptional 50% Surge in Net Profit to QAR 170 Million
Announcing Q1 2025 Financial Results
Estithmar Holding Q.P.S.C. announced a net profit of QAR 170 million for Q1 2025, reflecting a 50% increase compared to the same period last year. The company highlighted a 64% surge in revenue, reaching QAR 1.3 billion compared to QAR 797 million in Q1 2024. Gross profit rose to QAR 416 million, from QAR 196 million in Q1 2024. EBITDA reached QAR 273 million, marking a 53% increase. Earnings per share also grew by 57%, reaching QAR 0.047.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250421669945/en/
Estithmar Holding Reports an Exceptional 50% Surge in Net Profit to QAR 170 Million (Infographic: AETOSWire)
These strong financial indicators reflect the efficiency of Estithmar Holding’s investment strategy. International projects previously announced by Estithmar Holding started to have a tangible impact on its financial performance in revenue, profits and assets.
The results reflect the achievement of a strategic objective: a balanced contribution to profits and revenues from all four Clusters—Healthcare, Services, Tourism & Real Estate Development, and Contracting & Industries.
The Healthcare cluster posted significant growth in Q1 2025 driven by the cluster’s hospitals outside Qatar which contributed to revenue as new income streams, including Imam Al-Hassan Al-Mujtaba Hospital in Karbala, Al-Nasiriyah Teaching Hospital in Dhi Qar, Iraq, and Misrata Heart & Vascular Center in Libya. Moreover, the growing number of Hospitals outside Qatar in Iraq, Algeria and Libya reflects the confidence that governments across the MENA region have placed in the quality of services provided by Apex Health, the healthcare subsidiary of Estithmar Holding.
The Services cluster maintained leadership in Qatar, especially in Facilities Management and Catering. Expansion into KSA, Jordan and Iraq also significantly contributed to the Cluster’s profitability and the development of new income streams.
The Tourism & Real Estate Development cluster stayed on track with project delivery, including Rixos Baghdad (Iraq) and Rosewood Maldives Resort, driving a QAR 600 million increase in company assets in Q1 2025. Additionally, enhanced efficiency boosted profitability in existing projects, Lusail Winter Wonderland and Al Maha Island.
The Contracting & Industries cluster also made a notable contribution to revenue and profit growth, especially at the peak phase of project deliveries in the Kingdom of Saudi Arabia, including major projects such as the Red Sea Airport and the Yacht Club. The Cluster also secured new projects with Saudi PIF companies and improved local operational efficiency, enhancing profitability in Qatar.
Overall, Estithmar Holding’s Q1 2025 results highlight sustained growth aligned with its strategy to increase shareholder value on the short and the long term.
Group CEO Mr. Juan Leon stated:
“The exceptional rise in all financial indicators reflects the dedication of Estithmar’s team, and I look forward to working closely with them to build on Estithmar Holding’s growth story in Qatar and abroad. Analyzing these results, Estithmar Holding has demonstrated the ability to deliver sustained, diversified growth—both vertically and horizontally—paving the way for further expansion as investor confidence strengthens and our footprint continues to grow both locally and internationally.”
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20250421669945/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Antibody Solutions Launches Single Plasma B-Cell Services through Cellestive Discovery Platform22.4.2025 13:00:00 CEST | Press release
New, exclusive capability will allow antibody discovery clients to access more hits and more screening data than competing technologies Antibody Solutions, a leading provider of fit-for-purpose antibody discovery services, announced today that for the first time, single plasma B-cell discovery services will be part of the company’s exclusive Cellestive antibody discovery platform. The new capability completes a trifecta of B-cell services offered through Cellestive, which already includes discovery pathways for both activated and memory B-cells. The new plasma B-cell service is projected to be of particular value to clients pursuing difficult targets in antibody discovery, enabling them to leverage new processes and technologies while accessing broader, deeper data to inform their decision-making. “This really rounds out our Cellestive platform and allows us to robustly and efficiently interrogate single plasma B-cells for our clients,” said John Kenney, Phd, co-founder and president o
Sun Nuclear Announces Completion of Transition to CE Class IIb EU MDR Certification for Key Quality Management Solutions22.4.2025 12:04:00 CEST | Press release
SunCHECK® Software, SRS MapCHECK® and SunSCAN™ 3D DevicesAmong 15+ Solutions Awarded New Certification Sun Nuclear, a Mirion Medical company, announced today that its SunCHECK® Quality Management software and key radiation therapy Quality Assurance (QA) devices have been awarded CE Class IIb certification under the European Medical Devices Regulation 2017/745 (EU MDR). The transition to EU MDR Class IIb recognizes the safety and performance of Sun Nuclear solutions and confirms compliance with stringent safety requirements. Sun Nuclear solutions awarded Class IIb certification include: The SunCHECK® Platform, a comprehensive software application facilitating essential Patient and Machine QA workflows and centralized data management; Patient-specific QA solutions, including the ArcCHECK®, ArcCHECK®-MR, MapCHECK® 3 and SRS MapCHECK® devices, for measurement of radiation dose distributions against planned doses; Machine QA solutions, including the Daily QA™ 3, Daily QA™ 3-MR, IC PROFILER™
Regula Becomes the First to Verify All Dynamic Security Features in Remote Document Checks22.4.2025 12:00:00 CEST | Press release
With the recent update of its Document Reader SDK, Regula became the first identity verification (IDV) vendor to make it possible to verify all the dynamic security features of documents in real time. With the latest addition of Dynaprint® checks, the solution ensures more robust physical document authentication during remote onboarding. The innovation has arrived at a time when 58% of businesses globally face fake or modified IDs during digital onboarding. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250422724077/en/ Dynaprint in the Arizona’s driver’s license (Photo: Regula) Dynaprint® is a dynamic security feature consisting of two different images printed with lenticular technology. Depending on the angle of observation, only one image is visible at a time. Like all other dynamic security features, Dynaprint is crucial for securing identity documents from tampering, since it’s a tricky task to fake it without special e
Compass Pathways Announces Dosing Complete for All Participants in Part A of Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression22.4.2025 12:00:00 CEST | Press release
Highlights: Participants received a single dose of either 25 mg of COMP360 or placebo On track for disclosure of top-line 6-week primary endpoint results in late June Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that all participants have completed dosing in Part A of the COMP005 phase 3 trial for treatment resistant depression (TRD). Following pre-dosing activities, including washout from anti-depressant medications, if needed, participants received a single dose of either 25 mg of COMP360 or placebo. The Company is on track to disclose top-line 6-week primary endpoint results in late June. “Completing dosing of all participants in Part A of our 005 trial marks a critical milestone in our mission to address the pressing unmet need in treatment resistant depression,” said Kabir Nath, CEO Compass Pathways. “We are proud of this achievement which reflects our team’s commitment to scient
Egle Therapeutics to Highlight Novel Preclinical Findings for Regulatory T Cells Targeting Programs EGL-001 and EGL-002 With Poster Presentations at the 2025 AACR Annual Meeting22.4.2025 10:37:00 CEST | Press release
Egle Therapeutics, a clinical-stage biotechnology company developing therapies targeting regulatory T cells (Tregs) for immuno-oncology and autoimmune diseases, will present two posters at the American Association for Cancer Research Annual Meeting (AACR) 2025 being held in Chicago April 25-30, 2025. In the poster, entitled “Preferential tumor uptake and retention of EGL-001, an anti-CTLA4-IL2 mutein fusion antibody achieving selective tumor Treg depletion”. Egle Therapeutics unveils preclinical biodistribution data on EGL-001, a novel anti-CTLA4-IL2 mutein fusion antibody designed to selectively deplete tumor-infiltrating regulatory T cells (Tregs). EGL-001 mode of action combines competitive inhibition of IL-2 signaling and potent downregulation of surface CD25, leading to induction of Treg apoptosis. In vivo EGL-001 preferentially bound to the surface of Tregs due to their high CTLA-4 and CD25 expression and depleted them from the tumor microenvironment without affecting other immun
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom